Celtrix Moves Into Phase II With SomatoKine

13 January 1997

Having completed Phase I studies of SomatoKine (its novel IGF-BP3complex), which not only demonstrated safety at high doses but also stimulation of bone and connective tissue metabolism, US biopharmaceutical company Celtrix is now moving the product into Phase II testing.

SomatoKine is the recombinant equivalent of the natural complex formed by the anabolic hormone insulin-like growth factor-I (IGF-I) and its major binding protein (BP3). The company notes that severe physical trauma, extended illness and aging are frequently associated with abnormally-low blood levels of IGF-BP3.

Initial targets are elderly patients with reduced bone and muscle mass who have undergone hip fracture surgery. This patient population currently totals about 300,000 in the USA and is expected to grow substantially.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight